Pfizer/Aventis File For Exubera In Europe; No Timeline Yet On U.S. NDA
Executive Summary
Pfizer and Aventis have filed for European regulatory approval of the inhaled insulin Exubera
You may also be interested in...
Pfizer Exubera Post-Market Training Needs Greater Emphasis – Cmte.
Pfizer/Sanofi-Aventis' post-marketing training program for administering the inhaled insulin powder Exubera with a novel mechanical inhaler needs greater focus, FDA's Endocrinologic & Metabolic Drugs Advisory Committee said in a Sept. 8 review
Pfizer Exubera Post-Market Training Needs Greater Emphasis – Cmte.
Pfizer/Sanofi-Aventis' post-marketing training program for administering the inhaled insulin powder Exubera with a novel mechanical inhaler needs greater focus, FDA's Endocrinologic & Metabolic Drugs Advisory Committee said in a Sept. 8 review
Aventis Defense Against Sanofi: Strong Pipeline Or Irrational “Exubera-nce”?
Aventis is using the prospects of Genasense as its first line of defense against Sanofi's hostile takeover bid